- Home
- / Uk & Ireland solutions /
- UK & Ireland Market Access Pathways
UK & Ireland Market Access Pathways
- Home
- / UK & Ireland solutions /
- UK & Ireland Market Access Pathways
Uk and Ireland access consultancy
The key to success begins with a clear, well-defined pathway to product launch. With Kintiga, you gain a trusted partner who becomes an extension of your own team that understands the nuances behind every national opportunity with local expertise in the UK and Ireland. Prioritising the development of new medicines from small molecules to gene therapies is key to the success of pharmaceutical companies.
Early engagement can make a significant impact on the success of a product; aligning regulatory and reimbursement activities is critical to the success of providing access to patients.
Local Expertise and European purview
Europe’s healthcare landscape is anything but uniform. Each country operates with its own systems, priorities, and decision-making processes. From our base in the UK and Ireland, we help you navigate this complexity with strategies tailored to national contexts while preserving a unified value narrative. Our team offers expertise in strategic planning, stakeholder engagement, therapy area landscaping, and analytical services in every stage of product development.
Our team combines in-depth knowledge of local payer and HTA body dynamics with therapeutic expertise to craft compelling, country- specific approaches. Whether it’s developing persuasive value dossiers or preparing for pricing and reimbursement discussions, we ensure your product is ready to meet the expectations of stakeholders across the UK, Ireland and beyond.
Our services
Assess the appropriateness of clinical trials for the UK and European markets
HTA readiness assessments and strategic gap analysis
Early economic modelling
Target Product Profile testing
Country specific roadmaps and submissions planning including reimbursement strategy
Preparation of full local submissions and adaptations for additional national procedures
Facilitate early dialogue with payers and Patient Advocacy Groups
Structured and unstructured expert elicitation through acknowledged methods to confirm treatment pathways and product
positioning
Payer and expert advisory boards and Delphi panels of Key Opinion Leaders
Commercialisation and marketing strategy support
Development of value proposition and global value dossiers
Advise and support for pricing strategy
Delivering impact through excellence
Results speak louder than words. At Kintiga, our track record of success demonstrates our ability to deliver impactful market access strategies that align with your ambitions.
Let’s have a chat
We pride ourselves to have a personal relationship with our network of stakeholders, opinion leaders and clients, and we would love to get to know you as well. Feel free to reach out for a chat.
Julia Sus
Director, Market Access, UK
Claire Blaney
Director Market Access & Pricing Strategy Ireland
Priscila Mazzola
Director, Head of Value Communication in Value Communication
Ben Hendry
Director, Business Development UK & Ireland
Featured case studies
Delivering a Successful SMC Re‑Submission Through Strategic Alignment and Rapid Cross‑Functional Execution
Faster, Fairer, Broader: What NICE’s 2025–26 Annual Report Means for Market Access
NICE’s New Rulebook for Obesity Health Economics: What PMG50 Means for Modellers
PMI Pharma Summit
NICE Conference 2026
Poster Presentation: Increased trends of self-optimised submissions to NICE (HTA 199)
Our expertise:
UK and Ireland Access Consultancy
Our UK and Ireland team provide tailored strategic guidance and end-to-end support across development, launch, and lifecycle management, aligned with NICE, SMC, AWMSG, and NCPE pathways and evolving HTA expectations.
UK and Ireland Market Access Pathways
Success starts with a clear launch pathway. Kintiga offers UK and Ireland expertise, supporting NICE, SMC, AWMSG, and NCPE submissions with strong evidence alignment, payer negotiation, and stakeholder engagement to drive positive outcomes.
EU HTA Strategy Support
With extensive NICE submission experience, Kintiga is well positioned to support Joint Clinical Assessments, offering integrated solutions from JSC advice to JCA reporting for successful EU HTA outcomes.
Health Economics and Outcomes Research
Our Health Economists build and adapt economic models for the UK and Ireland, integrating local data, comparators, and care pathways. We also develop early pricing and access models to guide investment and evidence strategies aligned with payer expectations.
Pricing Strategy
Kintiga analyses pricing landscapes and benchmarks competitors to shape early pricing strategies. We integrate value messaging and design long-term frameworks like risk-sharing and managed entry agreements to ensure sustainable UK and Ireland market access.
Policy and Systems Navigation
Kintiga monitors policy changes across NHSE, DoH, HSE, and regional bodies to assess their impact on your product. We provide strategic engagement with key institutions and support managed access, conditional reimbursement, and policy initiatives to optimise market entry and sustainability.
Contact us
Ready to unlock your product’s potential in Europe’s complex healthcare landscape? Contact Kintiga today to discover how our market access strategy expertise can drive measurable impact for your product.
